Skip to main content

Table 1 Hazard ratio (HR) for clinical factors in the overall survival of lower-grade glioma

From: Systematic analysis of overall survival and interactions between tumor mutations and drug treatment

Factors N [n death] HR Univariate Multivariate
95 % CI p HR 95 % CI p
Age 261 1.07 1.05–1.09 5e−10 1.07 1.05–1.09 6e−9
Gender  
 Female 117 [30] 1      
 Male 144 [33] 0.88 0.54–1.45 0.620    
Temozolomide
 No 41 [24] 1      
 Yes 220 [39] 0.80 0.47–1.35 0.398    
R132H in IDH1
 Undetected 166 [45] 1      
 Detected 95 [18] 0.74 0.43–1.29 0.292    
Interaction drug-mutation
 Absent 181 [57] 1    1   
 Present 80 [6] 0.35 0.15–0.83 0.016 0.09 0.01–0.58 0.012
Histology
 Astrocytoma 107 [27] 1      
 Oligoastrocytoma/oligodendroglioma 154 [36] 0.67 0.40–1.10 0.112    
Tumor grade
 Grade II 77 [18] 1    1   
 Grade III 184 [45] 2.06 1.18–3.61 0.011 1.52 0.85–2.71 0.159
Laterality
 N.A. 1       
 Left 131 [28] 1      
 Midline 5 [1] 0.34 0.04–2.64 0.304    
 Right 123 [33] 0.82 0.49–1.37 0.443    
Tumor site
 N.A./other 3     1   
 Supratentorial, frontal lobe 160 [36] 1      
 Supratentorial, occipital lobe 5 [1] 0.71 0.10–5.20 0.736    
 Supratentorial, parietal lobe 23 [4] 0.84 0.30–2.38 0.748    
 Supratentorial, temporal lobe 70 [21] 1.86 1.08–3.22 0.026 1.22 0.70–2.11 0.481
Symptoms at diagnosis  
 N.A./other 19       
 Headaches 62 [18] 1      
 Mental status changes 22 [8] 1.84 0.80–4.27 0.153    
 Motor/movement changes 22 [6] 1.20 0.47–3.06 0.698    
 Seizures 119 [23] 0.58 0.31–1.08 0.087    
 Sensory changes 11 [2] 1.07 0.24–4.66 0.929    
 Visual changes 6 [2] 0.69 0.16–2.98 0.617